Lactobacilli as a source of natural microbicides against HIV-1

乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源

基本信息

  • 批准号:
    8136239
  • 负责人:
  • 金额:
    $ 36.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-30 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Topical microbicides formulated for vaginal use may help stem further spread of HIV-1 by reducing the number of new infections in women. One microbicide strategy under consideration is to strengthen the natural defenses in the vaginal mucosa where HIV-1 transmission takes place. Lactobacillus species are the predominant commensal bacteria found in genital tract secretions of healthy women. Under anaerobic conditions, these bacteria produce lactic acid and certain strains also produce hydrogen peroxide, a potent antimicrobial that has been shown to inactivate HIV-1 in vitro. Lactic acid bacteria also produce an array of antimicrobial molecules, termed bacteriocins, that are effective against competing organisms in the local milieu. Whether these natural antimicrobial factors can inhibit transmission and replication of HIV-1 in vaginal tissues is unknown. In preliminary studies, we have shown that conditioned media (CM) from cultures of Lactobacillus rhamnosus GG (LGG) inhibits replication of HIV-1 by 2 to 4 logs10 in primary CD4+ T lymphocytes, and this antiviral activity is distinct from both lactic acid and hydrogen peroxide. We hypothesize that natural bacteriocin-like molecule(s) produced by commensal lactic acid bacteria can enhance innate immuity in the vaginal mucosa and can inhibit infection and/or replication of HIV-1 in these target tissues. The goal of studies proposed in the exploratory (R21) phase is to purify and identify the low molecular weight active factor(s) produced by LGG bacteria, and determine the extent to which the LGG-purified factors (LGG-PF): 1) inhibit replication of HIV-1 in vitro, 2) modulate cell activation, proliferation and transcriptional regulation, and 3) affect the secretion of innate immune factors from primary epithelial cells from the human female reproductive tract. In the developmental (R33) phase, we will evaluate the effect of LGG-PF on HIV-1 infection and secretion of innate immune factors in primary explant cultures of human cervical and vaginal tissues, and will further evaluate cervicovaginal toxicity and inflammation in a mouse model developed for preclinical evaluation of topical vaginal microbicides. If the purified factor(s) secreted by LGG bacteria are shown to inhibit HIV-1 replication in relevant target cells in vitro, and modulate expression of innate immune factors in female genital tract tissue explants, this would provide evidence of a novel and beneficial effect that extends well beyond the established antimicrobial function of these bacteria. Moreover these results would lay the foundation for application of lactobacilli-derived products as HIV microbicides either alone or in combination with targeted compounds that block HIV-1 infection and replication.
描述:用于阴道使用的局部杀微生物剂可以通过减少妇女新感染的数量来帮助阻止HIV-1的进一步传播。一种正在考虑的杀微生物剂策略是加强发生HIV-1传播的阴道粘膜的自然防御。乳杆菌是健康女性生殖道分泌物中的主要共生菌。在厌氧条件下,这些细菌产生乳酸,某些菌株还产生过氧化氢,过氧化氢是一种有效的抗菌剂,已被证明在体外可以使HIV-1失活。乳酸菌还产生一系列被称为细菌素的抗微生物分子,这些分子能有效地对抗当地环境中的竞争生物。目前尚不清楚这些天然抗菌因子能否抑制HIV-1在阴道组织中的传播和复制。在初步研究中,我们发现来自鼠李糖乳杆菌(Lactobacillusrhamnosus GG,LGG)的条件培养液(CM,Lactobacillusrhamnosus GG,LGG)可抑制HIV-1在原代CD4+T淋巴细胞中复制2-4logs10,这种抗病毒活性有别于乳酸和过氧化氢。我们推测,共生乳酸菌产生的天然类细菌素分子(S)可以增强阴道粘膜的天然免疫,并能抑制HIV-1在这些靶组织中的感染和/或复制。在探索阶段(R21)提出的研究目标是纯化和鉴定LGG细菌产生的低分子活性因子(S),并确定LGG纯化因子(LGG-PF)的程度:1)抑制HIV-1的体外复制,2)调节细胞激活、增殖和转录调节,3)影响人类女性生殖道原代上皮细胞分泌天然免疫因子。在发育阶段(R33),我们将评估LGG-PF对人类宫颈和阴道组织原代外植体培养中HIV-1感染和天然免疫因子分泌的影响,并将在为临床前评估局部阴道杀菌剂而开发的小鼠模型中进一步评估宫颈阴道毒性和炎症。如果免疫球蛋白细菌分泌的纯化因子(S)在体外抑制HIV-1在相关靶细胞中的复制,并调节女性生殖道组织外植体中天然免疫因子的表达,这将为进一步研究这些细菌已有的抗菌功能提供新的有益效果的证据。此外,这些结果将为乳酸菌衍生产品作为艾滋病毒杀微生物剂的应用奠定基础,无论是单独使用还是与阻断艾滋病毒-1感染和复制的目标化合物结合使用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ruth Ingrid Connor其他文献

Ruth Ingrid Connor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ruth Ingrid Connor', 18)}}的其他基金

Feasibility study of LGG in HIV-exposed, breastfeeding infants in Tanzania.
LGG 在坦桑尼亚暴露于 HIV 的母乳喂养婴儿中的可行性研究。
  • 批准号:
    7497567
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7334948
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7931066
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7939941
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Feasibility study of LGG in HIV-exposed, breastfeeding infants in Tanzania.
LGG 在坦桑尼亚暴露于 HIV 的母乳喂养婴儿中的可行性研究。
  • 批准号:
    7119755
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7500866
  • 财政年份:
    2007
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactic acid bacteria in mucosal defense against HIV-1
乳酸菌在粘膜防御 HIV-1 中的作用
  • 批准号:
    7104531
  • 财政年份:
    2005
  • 资助金额:
    $ 36.91万
  • 项目类别:
Lactic acid bacteria in mucosal defense against HIV-1
乳酸菌在粘膜防御 HIV-1 中的作用
  • 批准号:
    7086805
  • 财政年份:
    2005
  • 资助金额:
    $ 36.91万
  • 项目类别:
PHENOTYPE AND CORECEPTOR USE IN HIV-1 TRANSMISSION
HIV-1 传播中的表型和辅助受体的使用
  • 批准号:
    2667786
  • 财政年份:
    1997
  • 资助金额:
    $ 36.91万
  • 项目类别:
PHENOTYPE AND CORECEPTOR USE IN HIV-1 TRANSMISSION
HIV-1 传播中的表型和辅助受体的使用
  • 批准号:
    6164190
  • 财政年份:
    1997
  • 资助金额:
    $ 36.91万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 36.91万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 36.91万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 36.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了